WO2005121105A1 - 新規3-フェニルテトラヒドロシンノリン-5-オール誘導体及びその医薬用途 - Google Patents
新規3-フェニルテトラヒドロシンノリン-5-オール誘導体及びその医薬用途 Download PDFInfo
- Publication number
- WO2005121105A1 WO2005121105A1 PCT/JP2005/010494 JP2005010494W WO2005121105A1 WO 2005121105 A1 WO2005121105 A1 WO 2005121105A1 JP 2005010494 W JP2005010494 W JP 2005010494W WO 2005121105 A1 WO2005121105 A1 WO 2005121105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen atom
- physiologically acceptable
- derivative
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a 3-phenyltetrahydrocinnoline-1.5-ol derivative, a physiologically acceptable salt thereof or a prodrug thereof, and a pharmaceutical use thereof.
- Malignant tumors are a group of cells that deviate from normal biological mechanisms, continue to proliferate in vivo, and cause death of the host if not treated.
- Surgical resection, irradiation, hormonal therapy or chemotherapy is generally used for the treatment of malignant tumors, and surgery is the first choice, especially for the treatment of solid malignant tumors.
- Radiation therapy, hormonal therapy, and chemotherapy are commonly used to treat malignant solid tumors that cannot be treated by adjuvant therapy or surgery before or after surgery.
- Hormone therapy, chemotherapy, and the like are used to narrow the area to be removed by surgery and to reduce or eliminate tumors that cannot be removed by surgery to prevent recurrence.
- Non-Patent Document 1 describes a cinnoline derivative having an action on the central nervous system
- Non-Patent Document 2 describes a cinnoline derivative having a monoamine oxidase inhibitory action
- Non-Patent Document 3 describes a cinnoline analog.
- the synthesis and reaction of is described, but the 3-phenyltetrahydrocinnolin-5-ol derivative represented by the general formula (1) described later in the present invention is not described in these documents. No mention is made that the -phenyltetrahydrocinnoline-5-ol derivative has an antitumor effect.
- Non-patent document 1 Rashmi K. Shah et al., Central Nervous System Active 5-Oxo-l, 4, 5, 6 , 7, 8_Hexahydrocinnolines, Journal of Medicinal Chemistry ⁇ 1976, vol.19, p.508-511 Structure-Activity Relationships, Journal of Medicinal Chemistry, 1998, vol.41, p.3812-3820
- Non-Patent Document 3 K. Nagarajan et al., Synthesis, Reactions of 4, 6, 7, 8-Tetrahydro-5 (1H) -ci dish olinones, Indian Journal of Chemistry, 1986, vol. 25B, p. 697- 708
- the present inventors have found that a novel 3-phenyltetrahydrocinnolin-5-ol derivative, a physiologically acceptable salt thereof or a prodrug thereof can be used for cell proliferation.
- the present inventors have found that they have inhibitory activity and antitumor activity, and have completed the present invention.
- Z represents MO- (O represents an oxygen atom), L (L ') N— (N represents a nitrogen atom) or A (B) CH— (C represents a carbon atom, Represents a hydrogen atom), and M represents a lower alkyl group having a lower alkoxy group, a lower alkylamino group or a saturated heterocyclic group as a substituent, or a lower alkyl group;
- L, L ′ May be bonded to each other to have a substituent, may represent a 4- to 8-membered cyclic structure group, or may each independently represent a hydroxyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, A hydrogen atom, a lower alkyl group or a hydrogen atom, and A represents a hydroxyl group, a lower alkyl group or a hydrogen atom; Is a substituted lower alkyl group, lower alkoxy group, carboxy group or X represents a lower alkyl
- the present invention relates to a 3-phenyltetrahydrocinnolin-5-ol derivative represented by the following formula, a physiologically acceptable salt thereof, or a prodrug thereof.
- the present invention provides the above 3-phenyltetrahydrocinnolin-5-ol derivative
- the present invention relates to a pharmaceutical composition containing a physiologically acceptable salt or a prodrug thereof as an active ingredient.
- the present invention relates to the use of the above 3-phenyltetrahydrocinnolin_5_ol derivative, a physiologically acceptable salt thereof or a prodrug thereof for producing a pharmaceutical composition for inhibiting cell growth.
- the present invention provides a use of the above-mentioned 3-phenyltetrahydrocinnoline_5_ol derivative, a physiologically acceptable salt thereof or a prodrug thereof for producing a pharmaceutical composition for preventing or treating tumor. About.
- the present invention relates to a method for inhibiting cell proliferation, which comprises administering the above-mentioned 3-phenyltetrahydrocinnolin-5_ol derivative, a physiologically acceptable salt thereof or a prodrug thereof to a mammal including human. And a method for inhibiting cell growth.
- the present invention relates to a method for preventing or treating a tumor, which comprises administering the above-mentioned 3-phenyltetrahydrocinnolin-5-ol derivative, a physiologically acceptable salt thereof or a prodrug thereof to a mammal including a human. And methods for preventing or treating tumors.
- a novel 3-phenyltetrahydrocinnolin-l_5_-ol derivative represented by the above general formula (1) which can be effectively used for prevention or treatment of tumor, and a physiologically acceptable derivative thereof
- the present invention provides a salt or a prodrug thereof, and a pharmaceutical composition comprising the same as an active ingredient, which is effective for inhibiting cell proliferation and preventing or treating a tumor.
- Examples of the lower alkyl group in the present invention include a linear or branched (C1-C5) alkyl group, and specific examples include a methyl group, an ethyl group, an n-propyl group, and an isopropyline group. , N-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl and the like.
- preferred groups include a methyl group, an ethyl group, an n-propyl group, and an isopropyl group.
- Examples of the lower alkoxy group in the present invention include a linear or branched (C1-C5) alkoxy group, and specific examples include a methoxy group, an ethoxy group, an n_propoxy group, Examples include an isopropoxy group, an n-butoxy group, an isobutoxy group, a tert-butoxy group, an n-pentyloxy group, and an isopentyloxy group.
- preferred groups include a methoxy group and an ethoxy group.
- Examples of the lower alkoxycarbonyl group in the present invention include a group in which the lower alkoxy group is bonded to a sulfonyl group, and are preferably a methoxycarbonyl group or an ethoxycarbonyl group.
- the lower alkylamino group in the present invention is an amino group in which one or two lower alkyl groups are bonded to each other, such as a methinoleamino group, an ethynoleamino group, a propylamino group, an isopropylinoleamino group, a dimethinoleamino group, and a dimethylamino group. And a dimethylamino group and a getylamino group.
- the saturated heterocyclic group in the present invention includes:! To 3 heteroatoms selected from N, S, or S, and may be substituted with a (CI to C5) alkyl group. And a saturated 5- to 7-membered ring group, for example, a pyrrolidino group, a 4-methylbiperazino group, a morpholino group, a piperidino group and the like.
- L and L ′ may be bonded to each other and may have a substituent.
- the group may be, for example, an azetidino group, a pyrrolidino group, a piperazino group, a piperidino group, a morpholino group, a homopiperidino group, a heptamethyleneimino group, a 4-methylbiperazino group, or a 4-benzylpiperazino group.
- Examples of the lower acetylamino group in the present invention include an amino group substituted by a linear or branched (C1-C5) acyl group. Specific examples include an acetylamino group and a propionylamino group. Groups, n-butyrylamino group, isobutyrylamino group, valerylamino group, isovalerylamino group, bivaloylamino group and the like, among which the acetylamino group is preferable.
- Examples of the halogen atom in the present invention include a fluorine atom, a chlorine atom, a bromine atom and a boron atom, and a fluorine atom or a bromine atom is preferable.
- B is a hydroxyl group, a carboxy group, a (C1-C5) alkoxycarbonyl group, an amino group, a (C1-C5) alkylamino group, A di (C1-C5) alkylamino group, a sulfamoyl group, a saturated heterocyclic group, an N-substituted rubamoyl group and a G_ (C1-C5) alkoxyl group (G is a carboxy group, an N-substituted rubamoyl group or a hydrogen atom (Cl to C5) alkyl groups substituted with one or more groups selected from the following.
- a carboxy group a (C1-C5) alkoxycarbonyl group, a di (C1-C5) alkylamino group or a (Cl-C5) alkyl group substituted with a saturated heterocyclic group is particularly preferred.
- (C1 to C5) alkoxycarbonyl group, (C1 to C5) alkylamino group, di (C1 to C5) anolequinoleamino group and saturated heterocyclic group are the above-mentioned alkoxycarbonyl group, anolequinoleamino group , A saturated heterocyclic group, and preferred groups are also the same.
- Examples of the substituent of the N-substituent rubamoyl group include a heterocyclic group-substituted (C1-C5) alkyl group such as a morpholinoethyl group, a 3-picolinole group, and a 4-picolyl group.
- a heterocyclic group-substituted (C1-C5) alkyl group such as a morpholinoethyl group, a 3-picolinole group, and a 4-picolyl group.
- the (C1-C5) alkoxy group in the G- (C1-C5) alkoxy group (G represents a carboxy group, an N-substituted rubamoyl group or a hydrogen atom) is the same as the above-mentioned alkoxy group.
- the substituent of the N-substituted rubamoyl group in G the same substituent as the above-mentioned N-substituted rubamoyl group in B may be substituted with a heterocyclic group such as a morpholinoethyl group, a 3- picolyl group or a 4-picolyl group (C1 To C5) alkyl groups.
- Specific examples of preferred groups for B include a carboxymethyl group and a dimethylamino- group.
- preferred groups for A include a hydroxyl group, a methyl group and a hydrogen atom, and a hydrogen atom is particularly preferred.
- X of the compound represented by the general formula (1) of the present invention is a methyl group, a methoxycarbinole group, an acetylamino, a methoxy group, a trifluoromethyl group, a nitro group, a cyano group, a halogen atom And a trifluoromethyl group is particularly preferable.
- X ' is preferably a trifluoromethyl group or a hydrogen atom, particularly preferably a hydrogen atom.
- X and X ' are substituted on the benzene ring, and the position is not particularly limited, but is preferably a 3-position substituent, Particularly preferred is a fluoromethyl group.
- Y is particularly preferably a methyl group, and Y 'is particularly preferably a hydrogen atom.
- Examples of the compound represented by the general formula (1) include compounds specifically shown in Table 1 below.
- Et represents an ethyl group
- Me represents a methyl group
- Ac represents an acetyl group
- iPr represents an isopropyl group.
- compound No .: compounds No. 13 to No. 39 are preferred from the viewpoint of antitumor effect, physical properties and other points.
- Compounds No. 13 to No. 27 are particularly preferred.
- 18 and No. 21 are particularly preferred.
- the 3-phenyltetrahydrocinnoline-5-ol derivative represented by the general formula (1) has an asymmetric carbon
- those compounds exist as optically active substances or racemic forms.
- an optically active compound or a racemic compound, a mixture thereof and the like are included, and a compound having an S configuration at the 5-position is preferable.
- a hydrate or a solvate of the 3-phenyltetrahydrocinnolin-5-ol derivative represented by the general formula (1) is also included in the present invention.
- physiologically acceptable salts in the present invention include salts with mineral acids such as hydrochloric acid and sulfuric acid, acetic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, tartaric acid, and methanesulfonic acid. And salts with organic acids such as p-toluenesulfonic acid.
- compounds having a carboxinole group in the molecule can form salts with alkali metals such as sodium and potassium.
- these salts are easily prepared by subjecting them to a usual salt formation reaction.
- the prodrug of the 3-phenyltetrahydrocinnoline-5ol derivative represented by the general formula (1) of the present invention or a physiologically acceptable salt thereof includes physiological conditions in vivo (for example, " Pharmaceutical Development, Vol. 7, Molecular Design ”, Hirokawa Shoten, 1990, pp. 163-198) under physiological conditions), for example, oxidation reaction, reduction reaction, hydrolysis with enzymes, gastric acid, etc. It is converted into a 3-phenyltetrahydrocinnolin-5-ol derivative represented by the general formula (1) of the present invention or a physiologically acceptable salt thereof by a reaction or the like, so that cell growth inhibitory activity ⁇ antitumor activity is reduced. And the like.
- Such a prodrug include a 3-phenyltetrahydrocinnoline-5-ol derivative represented by the general formula (1) or a physiologically acceptable salt thereof, which is present in the substituent Z.
- a compound in which a hydroxyl group which may be present in the substituent Z reacts with benzyl halide to form an ether group, a saturated heterocyclic group, a lower alkylamino group or the like which may be present in the substituent Z.
- the 3-phenyltetrahydrocinnolin-150-ol derivative, a physiologically acceptable salt thereof or a prodrug thereof of the present invention has a cell growth inhibitory activity, and more specifically, a breast cancer cell. It is effective as a cell growth inhibitor or an antitumor agent because it has tumor cell growth inhibitory activity.
- the cell growth inhibitor or the antitumor agent of the present invention comprises a 3_phenyltetrahydrocinnoline_5_ol derivative, a physiologically acceptable salt thereof or a prodrug thereof alone or mixed with an excipient or carrier.
- Pharmaceutically acceptable excipients such as excipients or carriers are selected, and their types and compositions are determined by the administration route and administration method. For example, in the case of an injection, salts, sugars such as gnorecose and mannitol are desirable.
- starch starch, lactose, crystalline cellulose, magnesium stearate and the like are desirable.
- auxiliaries, stabilizers, wetting agents, emulsifiers, buffer solutions or other commonly used additives may be included in the above preparations.
- the content of the compound of the present invention in the preparation varies depending on the preparation, but is usually from 0 :! to 100% by weight, preferably from 1 to 98% by weight.
- the active ingredient is usually contained in an amount of from 0 :! to 30% by weight, preferably from 1 to 10% by weight.
- oral preparations they are used in the form of tablets, capsules, powders, granules, solutions, dry capsules and the like together with additives.
- Capsules, tablets, granules, powders generally contain 5 to 100% by weight, preferably 25 to 98% by weight, of the active ingredient.
- the dose is determined according to the age, sex, weight, symptoms, treatment purpose, etc. of the patient.
- the therapeutic dose is usually 0.001 to parenteral administration:! OOmgZkg / day, and oral administration Then, 0.01 to 500 mgZkg /, preferably 0.1 to: 100 mg / kgZ, is administered to a patient once, and a certain dose is divided into 2 to 4 times.
- the 3-phenyltetrahydrocinnoline-l_5_ol derivative represented by the general formula (1) of the present invention Under physiological conditions in a living body (for example, physiological conditions as described in “Development of Drugs, Vol. 7, Molecular Design”, Hirokawa Shoten, 1990, pp. 163-198), for example, The compounds of the present invention also include so-called prodrugs which are converted by an oxidation reaction, reduction reaction, hydrolysis reaction or the like with an element or gastric acid and have an antitumor activity.
- the perhalogeno-substituted acetophenone derivatives represented by the following general formula (2) include compounds that can be purchased from Tokyo Chemical Industry Co., Ltd., etc., and are commercially available or easily obtainable by a production method according to known literature.
- the derivative may be used as a halogenating agent such as N-halogenosuccinimide; a simple halogen such as bromine or iodine; a salt such as pyridinium bromide perbromide, or the like at room temperature in a reaction solvent such as toluene or tetrahydrofuran. It can be easily obtained by reacting under reflux to obtain a halogen.
- E represents a halogen atom
- X and X ' have the same meaning as described above.
- the 1,3-cyclohexanedione derivative represented by the following general formula (5) has a certain amount of a commercially available compound. If necessary, the methylvinyl ketone derivative (3) and the malonic ester can be obtained according to the following scheme.
- Derivative (4) is heated from room temperature to reflux temperature in a solvent such as water, methanol or ethanol in the presence of a metal alkoxide such as sodium methoxide or sodium ethoxide or a metal hydroxide such as sodium hydroxide or potassium hydroxide. It is also prepared by reacting with [0041]
- R ′ represents a lower alkyl group
- Y and Y ′ have the same meaning as described above.
- Y ' is a hydrogen atom
- an oxidizing agent such as ammonium cerium (IV) nitrate, 2,3-dichloromethane_5,6-dicyano_ ⁇ -benzoquinone, or the like is reacted in acetone, methanol, tetrahydrofuran, or a mixed solvent thereof to obtain the following.
- the compound represented by the general formula (9) can be obtained.
- a compound represented by the general formula (9) is reduced in an organic solvent such as tetrahydrofuran, methanol, and ethanol in a reducing agent such as sodium borohydride, lithium aluminum hydride or lithium tri-tert-butoxyaluminum hydride. Is reacted at room temperature under ice-cooling to lead to 3_phenyltetrahydrocinnolin-5-ol which is a compound represented by the general formula (10).
- an acid anhydride such as succinic anhydride or gnoletalic anhydride, or methoxy acid is added to a compound represented by the general formula (10) in an organic solvent such as tetrahydrofuran, acetonitrile, dichloromethane or pyridine.
- a substituted lower acyl halide such as cetyl chloride is reacted, or a substituted lower fatty acid such as 4-dimethylaminobutyric acid or malonic acid mono-butyl ester is converted to dicyclohexylcarbodiimide, N-ethyl-N'_3-dimethylaminopropyl.
- the reaction can be carried out using WILEY 'INTERSCIENCE (described in the United States), and deprotection can be carried out when the protecting group is no longer needed to lead to the desired compound.
- ESI is an abbreviation for Electron Spray Ionization, and is one of ionization methods in molecular weight measurement.
- Reference Example 1 is an abbreviation for Electron Spray Ionization, and is one of ionization methods in molecular weight measurement.
- the toluene layer was washed with 400 ml of a saturated aqueous sodium hydrogencarbonate solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure of toluene, and distilled under reduced pressure to obtain the target compound (92.35 g, 81.7%).
- the target compound (1.58 g, 90.7%) was obtained as a white solid.
- the obtained organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
- the drying agent was separated by filtration and then concentrated under reduced pressure, and 2-propanol and hexane were added to the residue to crystallize.
- the crystals were collected by filtration to give the desired compound (343 mg, 82.7%).
- the obtained organic layer was washed with a saturated saline solution and dried over anhydrous sodium sulfate.
- the drying agent was separated by filtration and then concentrated under reduced pressure, and 2-propanol and hexane were added to the residue to crystallize.
- the crystals were collected by filtration to give the desired compound (300 mg, 73.2%).
- Example 1 the (2,2_dimethyl-5_oxo_ [1,3] dioxolan_4_yl) monoacetic acid obtained in Reference Example 6 was used.
- the colorless syrup (280 mg, 60.3%) obtained by the above treatment was dissolved in a mixture (14 ml each) of tetrahydrofuran, distilled water and acetic acid, and stirred at room temperature for 40 hours.
- the target compound was obtained by treating in the same manner as in Example 13 by using 3 picolylamine in place of 2- (4-morpholino) ethylamine in Example 13.
- Example 13 The same procedure as in Example 13 was repeated, except that 4-picolylamine was used instead of 2- (4 morpholino) ethylamine in Example 13, to obtain the desired compound.
- Example 13 5_ (3-carboxypropanoyl) oxy_7_methyl_3_ (3 —Trifluoromethylphenyl) -1
- 5 carboxymethoxyacetyloxy 7 methyl-3- (3-trifluoromethylphenyl) obtained in Example 2
- the target compound was obtained by treating in the same manner as in Example 13 using 5,6,7,8 tetrahydrocinnoline.
- Example 2 Example 5 was replaced with 5_ (3 carboxypropanoyl) oxy_7_methyl_3_ (3—trinoleolomethinolephenyl) _5,6,7,8-tetrahydrocinnoline in Example 13. 5_Carboxymethoxyacetyloxy 1 7 _methyl _ 3-(3-trifluorophenol) -1,5,6,7,8 tetrahydrocinnoline obtained in the place of 2- (4 morpholino) ethylamine The target compound was obtained by treating in the same manner as in Example 13 using 3 picolylamine.
- Example 13 In place of 5- (3 carboxypropanoyl) oxy 7-methyl-3- (3-trifnoroleolomethinolephenyl) _5,6,7,8-tetrahydrocinnoline in Example 13, it was obtained in Example 2.
- 5_Carboxymethoxyacetyloxyl 7_Methyl_3-(3-Trifluoromethylphenyl) -1,5,6,7,8-tetrahydrocinnoline is replaced with 2_ (4 morpholino) ethylamine instead of 4
- the target compound was obtained by treating in the same manner as in Example 13 using Picolinoleamine.
- the compounds of the present invention inhibit the growth of breast cancer cells and have an antitumor effect.
- the 3_phenyltetrahydrocinnolin-5-ol derivative represented by the general formula (1) of the present invention, a physiologically acceptable salt thereof, or a prodrug thereof can be used in a cell. Since it has a growth inhibitory activity, specifically, it has a growth inhibitory activity of tumor cells such as breast cancer cells, it is effective as a cell growth inhibitor ⁇ an antitumor agent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05748792A EP1757592A1 (en) | 2004-06-09 | 2005-06-08 | Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof |
JP2006514544A JPWO2005121105A1 (ja) | 2004-06-09 | 2005-06-08 | 新規3−フェニルテトラヒドロシンノリン−5−オール誘導体及びその医薬用途 |
BRPI0511879-4A BRPI0511879A (pt) | 2004-06-09 | 2005-06-08 | derivado de 3-feniltetraidrocinolin-5-ol, um sal fisiologicamente aceitável do mesmo, ou uma pró-droga de dito derivado ou sal, composição farmacêutica, uso de um derivado de 3-feniltetraidrocinolin-5-ol, um sal fisiologicamente aceitável do mesmo, ou pró-droga de dito derivado ou sal, e, métodos para a inibição da proliferação celular e para a prevenção ou tratamento de tumores |
CA002568301A CA2568301A1 (en) | 2004-06-09 | 2005-06-08 | 3-phenyltetrahydrocinnolin-5-ol derivatives and medicinal use thereof of |
US11/597,232 US20080039468A1 (en) | 2004-06-09 | 2005-06-08 | Novel 3-Phenyltetrahydrocinnolin-5-Ol Derivative and Medicinal Use Thereof |
AU2005252074A AU2005252074A1 (en) | 2004-06-09 | 2005-06-08 | Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-171426 | 2004-06-09 | ||
JP2004171426 | 2004-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121105A1 true WO2005121105A1 (ja) | 2005-12-22 |
Family
ID=35502995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/010494 WO2005121105A1 (ja) | 2004-06-09 | 2005-06-08 | 新規3-フェニルテトラヒドロシンノリン-5-オール誘導体及びその医薬用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080039468A1 (ja) |
EP (1) | EP1757592A1 (ja) |
JP (1) | JPWO2005121105A1 (ja) |
KR (1) | KR20070029735A (ja) |
CN (1) | CN1964953A (ja) |
AU (1) | AU2005252074A1 (ja) |
BR (1) | BRPI0511879A (ja) |
CA (1) | CA2568301A1 (ja) |
RU (1) | RU2006146988A (ja) |
TW (1) | TW200606156A (ja) |
WO (1) | WO2005121105A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090884A1 (ja) * | 2007-01-23 | 2008-07-31 | Nippon Kayaku Kabushiki Kaisha | 新規トリフルオロメチルフェニルテトラヒドロシンノリン誘導体及びその医薬用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052866A1 (ja) * | 2002-12-10 | 2004-06-24 | Nippon Kayaku Kabushiki Kaisha | 3−フェニル−シンノリン類縁体とそれを用いた抗腫瘍剤 |
-
2005
- 2005-06-08 AU AU2005252074A patent/AU2005252074A1/en not_active Abandoned
- 2005-06-08 TW TW094118915A patent/TW200606156A/zh unknown
- 2005-06-08 US US11/597,232 patent/US20080039468A1/en not_active Abandoned
- 2005-06-08 JP JP2006514544A patent/JPWO2005121105A1/ja active Pending
- 2005-06-08 EP EP05748792A patent/EP1757592A1/en not_active Withdrawn
- 2005-06-08 RU RU2006146988/04A patent/RU2006146988A/ru not_active Application Discontinuation
- 2005-06-08 WO PCT/JP2005/010494 patent/WO2005121105A1/ja not_active Application Discontinuation
- 2005-06-08 CA CA002568301A patent/CA2568301A1/en not_active Abandoned
- 2005-06-08 KR KR1020067025395A patent/KR20070029735A/ko not_active Application Discontinuation
- 2005-06-08 BR BRPI0511879-4A patent/BRPI0511879A/pt not_active Application Discontinuation
- 2005-06-08 CN CNA200580018872XA patent/CN1964953A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052866A1 (ja) * | 2002-12-10 | 2004-06-24 | Nippon Kayaku Kabushiki Kaisha | 3−フェニル−シンノリン類縁体とそれを用いた抗腫瘍剤 |
Non-Patent Citations (1)
Title |
---|
NAGARAJAN RK ET AL: "Synthesis and Reactions of 4,6,7,8-Tetrahydro-5 (1H)-cinnolonones.", INDIAN JOURNAL OF CHEMISTRY., vol. 25B, no. 7, 1986, pages 697 - 708, XP002976309 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090884A1 (ja) * | 2007-01-23 | 2008-07-31 | Nippon Kayaku Kabushiki Kaisha | 新規トリフルオロメチルフェニルテトラヒドロシンノリン誘導体及びその医薬用途 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0511879A (pt) | 2008-01-15 |
US20080039468A1 (en) | 2008-02-14 |
CA2568301A1 (en) | 2005-12-22 |
CN1964953A (zh) | 2007-05-16 |
RU2006146988A (ru) | 2008-07-20 |
EP1757592A1 (en) | 2007-02-28 |
AU2005252074A1 (en) | 2005-12-22 |
TW200606156A (en) | 2006-02-16 |
KR20070029735A (ko) | 2007-03-14 |
JPWO2005121105A1 (ja) | 2008-04-10 |
EP1757592A8 (en) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102029951B1 (ko) | 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도 | |
RU2155187C2 (ru) | Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека. | |
CA3130456C (en) | Heterotricyclic derivative compound and use of same | |
JP3836436B2 (ja) | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 | |
TWI389902B (zh) | C-met/肝細胞生長因子受體(hgfr)抑制劑之多晶型體 | |
JP2024514703A (ja) | ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 | |
RU2724333C2 (ru) | Производное 1,3,5-триазина и способ его применения | |
EP1557415B1 (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
JPH09508924A (ja) | 置換3−アリールイデン−7−アザオキシインドール化合物及びその製造方法 | |
WO2019057123A1 (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
JPWO2005095389A1 (ja) | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 | |
WO2023280182A1 (zh) | 作为kat6抑制剂的化合物 | |
HUT64952A (en) | Benzofuranyl-methyl-thio-alkane-carboxylic acid derivatives and thiophenyl ones | |
WO2024051502A1 (zh) | 喜树碱-7-乙基胺衍生物及其制备方法和应用 | |
WO2023116824A1 (zh) | 哒嗪酮类化合物及其制备方法、药物组合物和应用 | |
WO2005121105A1 (ja) | 新規3-フェニルテトラヒドロシンノリン-5-オール誘導体及びその医薬用途 | |
WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
JPH07267941A (ja) | 3−アリール−グリシド酸エステル誘導体およびその製造方法 | |
AU2003289002B2 (en) | 3-phenyl-cinnoline homologue and antitumor agent containing the same | |
EP1431280A1 (en) | Aryl sulfamate derivatives | |
CN113683613B (zh) | 一种多环吡啶肟基化合物及其药物组合物和用途 | |
JP2006505578A (ja) | 神経弛緩活性を有する5−(2−(4−(1,2ベンズイソチアゾール−3−イル)−1−ピペラジニル)エチル)−6−クロロ−1,3−ジヒドロ−2h−インドール−2−オンのアシル誘導体 | |
CN112480100B (zh) | 吡咯烷酮衍生物 | |
JP2010070452A (ja) | 新規トリフルオロメチルフェニルテトラヒドロシンノリン誘導体とその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005748792 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2568301 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005252074 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006514544 Country of ref document: JP Ref document number: 1020067025395 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580018872.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005252074 Country of ref document: AU Date of ref document: 20050608 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005252074 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006146988 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11597232 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005748792 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0511879 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11597232 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005748792 Country of ref document: EP |